

Axovant Sciences Ltd.  
Form SC 13G  
February 16, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No. )\***

---

**Axovant Sciences Ltd.**

(Name of Issuer)

**Common shares, \$0.00001 par value per share**

(Title of Class of Securities)

**G0750W104**

(CUSIP Number)

**December 31, 2015**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



Edgar Filing: Axovant Sciences Ltd. - Form SC 13G

CUSIP No.: G0750W104

- |   |   |                                      |  |
|---|---|--------------------------------------|--|
| (1)   | Names of Reporting Persons<br>Roivant Sciences Ltd.                                     |                                      |  |
| (2)   | Check the Appropriate Box if a Member of a Group (See Instructions)                     |                                      |  |
|   | (a)   | <input type="radio"/>                |  |
|   | (b)   | <input type="radio"/>                |  |
| (3)   | SEC Use Only  |                                      |  |
| (4)   | Citizenship or Place of Organization<br>Bermuda   |                                      |  |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | (5)   | Sole Voting Power<br>75,000,000      |  |
|   | (6)   | Shared Voting Power<br>0             |  |
|   | (7)   | Sole Dispositive Power<br>75,000,000 |  |
|   | (8)   | Shared Dispositive Power<br>0        |  |
| (9)   | Aggregate Amount Beneficially Owned by Each Reporting Person<br>75,000,000              |                                      |  |
| (10)  | Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="radio"/>                |  |
| (11)  | Percent of Class Represented by Amount in Row (9)<br>75.6%(1)                           |                                      |  |
| (12)  | Type of Reporting Person (See Instructions)<br>CO                                       |                                      |  |

---

(1) All share percentage calculations in this Schedule 13G are based on 99,150,000 common shares, \$0.00001 par value per share, of Axovant Sciences Ltd. outstanding as of February 9, 2016.

Edgar Filing: Axovant Sciences Ltd. - Form SC 13G

- Item 1(a).** Name of Issuer.  
The name of the issuer is Axovant Sciences Ltd. (the Issuer ).
- Item 1(b).** Address of Issuer's Principal Executive Offices.  
The Issuer's principal executive offices are located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.
- Item 2(a).** Name of Person Filing.  
This Schedule 13G (this **Schedule 13G** ) is filed on behalf of Roivant Sciences Ltd. ( **Roivant** ).
- Item 2(b).** Address of Principal Business Office or, if none, Residence.  
The principal business address of Roivant is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.
- Item 2(c).** Citizenship.  
Roivant is an exempted limited company incorporated under the laws of Bermuda.
- Item 2(d).** Title of Class of Securities.  
This Schedule 13G relates to common shares, \$0.00001 par value per common share, of the Issuer.
- Item 2(e).** CUSIP No.  
The CUSIP number of the Issuer is G0750W104.
- Item 3.**  
Not applicable.

**Item 4.**

**Ownership.**

Each Reporting Person:

- |     |   |  |
|-----|---|--|
| (a) | Amount beneficially owned:                              |  |
|     |   | 75,000,000   |
| (b) | Percent of class:                                       |  |
|     |   | 75.6%  |
| (c) | Number of shares as to which each reporting person has: |  |
|     |   |  |
|     | (i)   | Sole power to vote or to direct the vote:                |
|     |   | 75,000,000   |
|     | (ii)  | Shared power to vote or to direct the vote:              |
|     |   | 0  |
|     | (iii)   | Sole power to dispose or to direct the disposition of:   |
|     |   | 75,000,000   |
|     | (iv)  | Shared power to dispose or to direct the disposition of: |
|     |   | 0  |

**Item 5.**

**Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following:

**Item 6.**

**Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7.**

**Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not applicable.

**Item 8.**

**Identification and Classification of Members of the Group.**

Not applicable.

**Item 9.**

**Notice of Dissolution of Group.**

Not applicable.

**Item 10.**

**Certification.**

Not applicable.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**DATE:** February 16, 2016

**ROIVANT SCIENCES LTD.**

By: */s/ Marianne Romeo Dinsmore*  
Name: Marianne Romeo Dinsmore  
Title: Authorized Signatory